Stocks · News reference
CRISPR Therapeutics Data From Its Phase 1 Clinical Study Of CTX Shows 79% Mean Reductions From Baseline For ANGPTL3, 48% Maximum For Triglycerides
CRISPR Therapeutics (NASDAQ:CRSP) today presented durability data from its Phase 1a clinical trial evaluating CTX310®, an investigational, in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3. A single-course
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 28, 2026, 2:35 PM
- Checked
- Aug 28, 2026, 2:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target
Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
Read original at benzingaVertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Vertex Pharmaceuticals strengthens its dominant position in the cystic fibrosis market after competitor Sionna Therapeutics failed a clinical trial for its CF drug candidate. With continued CF portfolio improvements, patent exclusivity until the late 2030s, and promising newer medicines like Casgevy for rare blood diseases and Journavx for pain management, Wall Street remains bullish on Vertex's growth prospects.
Read original at the-motley-fool